SAN FRANCISCO--(BUSINESS WIRE)--FibroGen, Inc., today announced preliminary clinical findings from two ongoing, open-label phase 2 studies demonstrating that FG-4592, its investigational oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor (PHI) therapy for anemia, reduced blood pressure in hypertensive patients, reduced cholesterol levels, and improved the ratio of HDL to LDL in lipid profiles, in patients with chronic kidney disease (CKD). Hypertension and dyslipidemia are two of the major risk factors associated with increasing cardiovascular risk in patients with advanced CKD Stages 3b through 5.
